The possible value of diagnosing MCI-DLB and treatment options

Dementia with Lewy Bodies (DLB) is a well-described clinical entity. DLB patients can be treated with acetylcholinesterase inhibitors (AChEI's). However, should we also treat patients who have but part of the symptoms and who are currently described as MCI-DLB? Will these MCI-DLB patients benef...

Full description

Saved in:
Bibliographic Details
Published inTijdschrift voor gerontologie en geriatrie Vol. 40; no. 4; p. 168
Main Authors Feitsma, M T, van Laar, T, Dautzenberg, P L J
Format Journal Article
LanguageDutch
Published Netherlands 01.09.2009
Subjects
Aged, 80 and over
Cholinesterase Inhibitors - therapeutic use
Early Diagnosis
Female
Humans
Lewy Body Disease - diagnosis
Lewy Body Disease - drug therapy
Phenylcarbamates - therapeutic use
Prognosis
Rivastigmine
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Dementia with Lewy Bodies (DLB) is a well-described clinical entity. DLB patients can be treated with acetylcholinesterase inhibitors (AChEI's). However, should we also treat patients who have but part of the symptoms and who are currently described as MCI-DLB? Will these MCI-DLB patients benefit from AChEI's in terms of direct effect on cognition and behaviour and final outcome? Two cases are presented to demonstrate the clinical features of MCI-DLB and the effect of treatment with rivastigmine (AChEI). The discussion then focuses on the possible value of diagnosing MCI-DLB and if this diagnosis should result in a different medication treatment than the diagnosis MCI-AD, for which AChEI medication is not recommended.
ISSN:0167-9228